G. Mueller

Evidence of a role for RANKL in the development of myeloma bone disease.

P. Croucher, K. Vanderkerken, E. de Leenheer, 2004, Current opinion in pharmacology.

Clinical disorders of bone resorption.

P. Croucher, G. Russell, C. Shipman, 2001, Novartis Foundation symposium.

Apomine™, an inhibitor of HMG‐CoA‐reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo

P. Croucher, R. Russell, K. Vanderkerken, 2007, International journal of cancer.